KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-cash Items (2016 - 2025)

Rigel Pharmaceuticals has reported Non-cash Items over the past 14 years, most recently at $3.2 million for Q3 2025.

  • Quarterly results put Non-cash Items at $3.2 million for Q3 2025, up 28.0% from a year ago — trailing twelve months through Sep 2025 was $3.2 million (up 28.0% YoY), and the annual figure for FY2024 was $10.6 million, down 56.52%.
  • Non-cash Items for Q3 2025 was $3.2 million at Rigel Pharmaceuticals, roughly flat from $3.2 million in the prior quarter.
  • Over the last five years, Non-cash Items for RIGL hit a ceiling of $24.4 million in Q4 2023 and a floor of $1.6 million in Q4 2022.
  • Median Non-cash Items over the past 5 years was $5.0 million (2022), compared with a mean of $8.4 million.
  • Biggest five-year swings in Non-cash Items: soared 1418.93% in 2023 and later crashed 82.88% in 2024.
  • Rigel Pharmaceuticals' Non-cash Items stood at $6.8 million in 2021, then crashed by 76.44% to $1.6 million in 2022, then soared by 1418.93% to $24.4 million in 2023, then plummeted by 56.52% to $10.6 million in 2024, then crashed by 69.81% to $3.2 million in 2025.
  • The last three reported values for Non-cash Items were $3.2 million (Q3 2025), $3.2 million (Q2 2025), and $3.5 million (Q1 2025) per Business Quant data.